Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"Dr. Sytkowski will bring to bear his considerable expertise on the development and the marketing of PT-401, our lead pharmaceutical product being developed for the treatment of anemia.
We look forward to working with him on this project and any future endeavors."
Ann
stockhldr:
"DNAG's last contractor? Mark Shriver, who gave DNAG ANCESTRY by DNA! Not bad!"
Can you post the link?
Take care,
Ann
9car:
'Tis a lady named Michael:
http://www.donaldgeikie.com/kdsaunders.html
Take care,
Ann
I still think Jever000 is GEOB...GEOB at one time stated he was leaving (after all the pumping?) then returned as Jever000 - mispelling, same hype & all...nothing wrong w/that...just remember, the old Jever was Jever00 NOT Jever000. Just MHO
Ann
From NY Times article:
" DNAPrint Genomics maintains the largest Native American DNA Database in North America."
Ann
DNAP Pharmaceutical - We're all in the know re: the following:
"DNAPrint genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Pre-clinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to better design actual trials and are targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests."
Ann
DNAP Pharmaceuticals:
On October 12, 2005, we formed DNAPrint Pharmaceuticals, Inc., a wholly-owned pharmaceutical subsidiary focused on personalized medicine.
Think it'll bear fruition? Wait 'n see game to date.
Ann
DNAP article highleted in NY Times:
http://cache.zoominfo.com/cachedpage/?archive_id=0&page_id=1509732485&page_url=%2f%2fwww.mar...
Ann
DNAP New Website: - NOT - sorry - layout on page listed it as website. I should have looked it over more carefully before posting. However, at least we know the DBA (Doing Business As) filing went through.
Ann
It looked like a lead-in...
Doing my best for all,
Will keep you updated and informed to my best capabilities...
whatever that may be...lol
Ann
This seems to be the "new" DNAP Pharmaceuticals web site:
http://www.sciencewow.com/
Ann
DNAP's Ancestry test highleghted in NY Times:
http://cache.zoominfo.com/cachedpage/?archive_id=0&page_id=1509732485&page_url=%2f%2fwww.mar...
Ann
FINALLY - DNAP Pharmaceuticals & New Website:
http://www.zoominfo.com/search/CompanyDetail.aspx?CompanyID=49040752&cs=QEC7E1woc
Ann
Application in latest Press Release:
"SARASOTA, FL -- (MARKET WIRE) -- 07/31/06 -- DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced that its subsidiary, DNAPrint Pharmaceuticals, Inc., has completed the development of the so-called "Western blot" method, an analytical procedure that identifies a protein according to its interaction with a specific antibody, a significant step in the development of its PT-401-based proprietary drug to treat anemia.
"The method ensures the identification of PT-401 and meets the requirements of the Food and Drug Administration for a successful Investigational New Drug filing," stated Hector J. Gomez, M.D., Ph.D., Chairman and Chief Medical Officer of DNAPrint Genomics and the Company's DNAPrint Pharmaceuticals subsidiary."
Ann
Description of Western Blot:
Total protein western blots are manufactured with high quality proteins from documented tissues. The tissues are excised, immediately frozen, and then pathologically identified. Proteins are isolated from these tissues using BioChain's proprietary techniques. The proteins are separated by 4-20% gradient SDS-PAGE gel electrophoresis, and transferred onto a PVDF membrane. Human placenta protein is used as an interblot control lane in each blot for protein expression comparison between different blots. A 10 kd to 250 kd prestained protein marker can be visualized on each blot. These blots are suitable for use in both radioactive and non-radioactive detection. Total protein western blots are supplied ready for use, so that you can immediately screen the protein of interest without the hassle of obtaining hard to find tissues and processing the proteins yourself.
Ann
I don't recall seeing anything on this event:
(webcast/powerpoint)
http://www.shareholder.com/DNAPrint/medialist.cfm
Ann
Info. from Stockhldr & DNAP news release:
http://www.westernblotinfo.com/
Ann
Posted by alo on IV:
(here you go, Bag):
http://www.pcwelt.de/news/englishnews/114553/Crime pays for DNAPrint genomicsIt has become hard to tune in to one?s favorite crime show on television these days without running across an odd-looking, eccentric character depicting the "scientist," using the latest technologies to help identify either the victim or perpetrator of some gruesome crime. Of course, the reality is that the use of modern forensic science has indeed benefited from the tremendous advances in genomic technologies, and the genomics industry has come forward with tools that can be used successfully by even the most conventional-looking laboratory worker. It has become hard to tune in to one's favorite crime show on television these days without running across an odd-looking, eccentric character depicting the "scientist," using the latest technologies to help identify either the victim or perpetrator of some gruesome crime. Of course, the reality is that the use of modern forensic science has indeed benefited from the tremendous advances in genomic technologies, and the genomics industry has come forward with tools that can be used successfully by even the most conventional-looking laboratory worker.
A good example recently appeared not on the latest episode of CSI: Miami, but in fact, on the local news in the San Francisco Bay area. According to a story in May on KGO-TV, an ABC affiliate in San Francisco, a murder in the Mammoth Lakes area in California's southern Sierras has become a test case for the use of genomics in forensic science and could become the model for the future of genomic crime fighting. In May 2003, a body was found in a shallow grave at a campground. The remains were sent to the San Francisco Medical Examiner's office, which determined that the victim was a woman of Southeast Asian descent. However, the focus of the investigation changed after a sample was sent to DNAPrint Genomics of Sarasota, Florida, as use of their DNAWITNESS technology determined that the victim was actually of Native-American descent. Using new techniques from DNAPrint and other scientific laboratories, authorities were able to build a sketch of the woman that matched an artist's sketch drawn from a description of a woman who visited the campground in the fall of 2002.
DNAWITNESS 2.0 is used by law enforcement agencies to determine the likely genetic heritage of DNA samples obtained from crime scenes -- thereby narrowing the potential pool of suspects or victims. Earlier forensic DNA products acted more like a fingerprint and could only be used to match DNA specimens -- which is of little use without a set of likely suspects from whom DNA can be obtained. Instead, DNAWITNESS provides the percentage of genetic makeup of an individual from four possible groups: Sub-Saharan African, Native American, East Asian, and Indo-European.
According to Richard Gabriel, the company's president and CEO, DNAPrint technology has impacted a number of high-profile murder investigations. A case in Concord, California, had targeted Hispanic- or Asian-descent gang members in a murder, based on eyewitness reports. However, it turned out that the perpetrator was actually Caucasian, based on the results from the DNAWITNESS assay.
DNAPrint technology makes use of ancestry informative markers (AIMs), which are particular single nucleotide polymorphisms (SNPs) identified in the human genome. The company has filed patent applications covering several key AIMs that they have linked to human disease, reactions to particular drugs, forensics, and human heredity and identity. They have verified these markers in high-throughput screens and have applied them for genome-screening applications. The AIMs are mapped using the proprietary mapping by admixture linkage disequilibrium (MALD) method. MALD allows known statistical data about population structure to be exploited to reduce substantially the number of SNPs analyzed -- leading to more cost-effective analysis. Thus, by analysis of a limited number of SNPs in a particular sample, the company can assign likely genetic heritage.
Last August, the company unveiled the next generation of its genetic profiling package, DNAWITNESS 2.5. The new package included the RETINOME genetic test to predict eye color from a DNA sample, again based on the analysis of a select set of SNPs. Eye color has its genetic basis in a host of genes. RETINOME was developed from a genome screen of tens of thousands of SNPs in thousands of European subjects. The most recent blind validation test for 65 individuals of predominant (greater than 80 percent) European ancestry, between the ages of 10 and 60 years of age, showed greater than 97 percent accuracy.
Robert M. Frederickson is a biotech writer based in Seattle. E-mail: rfreder@yahoo.com.
Ann
TY, Team - later,
Ann
Team:
What's that about? - I'm not that knowledgeable, so just curious - been happening at end of each trading day.
Take care,
Ann
A very nice day to you, Stockhldr
Ann
Morning to you too, Dorsey - have a wonderful day!
Ann
Human Resources Position: - Lab Technician -
CAREERS
Lab Technician
DNAPrint Genomics, Inc., is currently accepting applications for a laboratory technician position available for a B.S. or M.S.-level scientist who has previous experience working in either an academic or forensics laboratory. This person should be well versed in not only classical genetics but modern genome based techniques. Technician will operate capillary electrophoresis and automated Beckman equipment (multimek liquid handling system, Ultra High Throughput instruments). This person will be involved in the production of customer results as well as research and development work on a variety of projects. Additionally, general lab maintenance and equipment calibration will form a portion of this position. An applicant should be capable of working within the confines of pre-defined standard operating procedures, and of developing new ones as the needs of the company change. Experience and familiarity with DNA extraction, PCR, sequencing, fragment analysis and other molecular biology techniques is required for this position.
Salary is commensurate with experience. Benefits include health insurance, 401K plan, annual leave. Job is located at the corporate headquarters in Sarasota, Florida. No phone calls. Please send resume and cover letter by fax, e-mail, or U.S. mail to:
Human Resources
DNAPrint Genomics, Inc.
900 Cocoanut Avenue
Sarasota FL 34236
FAX: 941-955-9770
lfranklin@dnaprint.com
Ann
Police One - featured DNAP forensic products:
http://www.policeone.com/police-products/investigation/DNA-forensics/
Ann
Sorry - just up - let me rephrase that:
"They may be a repeat - but, never hurts to re-read news from time to time. There also may be newbies who never saw."
Now for my coffee - lol
Ann
Stock:
They may be a repeat - but, never hurts to re-read time to time. There also may newbies who never saw.
Take care,
Ann
DNAP in Big Guy Directory:
http://www.thezoomlist.com/drugs_mfg/drug_manufacturing_research/side.htm
Ann
Here's more "DNAPrint Pharmaceuticals" news:
http://www.marketwire.com/mw/release_html_b1?release_id=112989
Ann
This news not posted either:
http://www.marketwire.com/mw/release_html_b1?release_id=129996
Ann
I don't recall seeing this News Release:
http://www.marketwire.com/mw/release_html_b1?release_id=138440
Amm
4/05 - Wallstreet transcript - DNAP & AMGEN - what is under discussion on SUPER EPO:
TWST: What about the pharmaceutical prospects?
Mr. Gabriel: While we see our forensics business as an engine that will generate revenues for the company, one of our fundamental goals is to apply this technology to drug development. We recently took a big step in that direction by acquiring an exclusive worldwide license from Harvard Medical School's Beth Israel Deaconess Medical Center (BIDMC).
This is a royalty bearing agreement that creates an opportunity for DNAPrint genomics to develop a new, more potent and longer acting form of the anemia drug Erythropoietin (EPO). EPO is currently commercialized by Amgen, Johnson & Johnson and Roche in a worldwide market that exceeds $10 billion and that has been growing at an average annual rate of 21%. The human gene that produces EPO was cloned in 1985 and in 1989, scientists at Amgen introduced to market a recombinant form under the trade name EPOGEN', a drug that many credit for the rise of Amgen in the
1990s as one of the world's most successful biotechnology companies ever. Erythropoietin has been approved by the Food and Drug Administration as a treatment for anemia associated with renal failure, cancer chemotherapy, and Zidovudine-treated HIV-infected patients and to reduce blood transfusion in surgery patients. Our goal is to develop and market a 'super'-EPO, a more powerful form of the drug. This is a perfect fit within the company's overarching strategy to utilize recent genomics and chemistry advances made by our researchers to develop next-
generation drugs that maximize efficacy and minimize side effects by tailoring medication for specific individuals and well-defined population sectors.
Ann
Stockhldr:
You may want to check out the convestation re: EPO on Investor's Village - interesting.
Take care,
Ann
IMHO - strange how Jever000's behavior mimics GEOB's, bad spelling and all, who left suddenly and unexplainably, after being as gung-ho on DNAP as Jever is now, and who has all the similar opinions GEOB did. - But, hey...JMHO
Ann
Gavin Menziez - speaker at E-Symposium - DNAP's:
http://www.1421.tv/pages/evidence/content.asp?EvidenceID=142
Ann
In a nutshell: E-Symposium is a web conference.
Ann
E-Symposium a Ground-Breaking Innovation: (demo)
http://e-symposium.bright-talk.com/brightcast/idsousa040504
Ann
Following are the hosts of E-Symposium:
http://www.ancestry.e-symposium.com/host.php
Ann
Michi:
OT:
" I forgot everything about DNAG, frudlago, jev, spook, dew, illwill and so on."
Well, here you are back on board - lol
Take care,
Ann
Michiko-san:
OT:
I have now had my coffee and awake. A lazy, relaxing day for me.
You have a nice one also,
Ann